ProCyte Corp. underwriters have exercised their overallotmentoption to purchase an additional 275,000 shares of commonstock (NASDAQ:PRCY). William Blair & Co. and Dain BosworthInc. co-managed the offering.
The Kirkland, Wash., company's offering of 2 million shares at$9 each was completed Feb. 9.
ProCyte has 9.83 shares outstanding on a fully diluted basis.The company focuses on therapies based on proprietarypeptide-copper compounds for tissue repair and healing.ProCyte's stock closed unchanged Friday at $9.13 a share.
(c) 1997 American Health Consultants. All rights reserved.